Irpagratinib
- Generic Name
- Irpagratinib
Abbisko's Irpagratinib-Atezolizumab Combination Shows Promising Results for Advanced Liver Cancer
• Abbisko Therapeutics will present updated Phase 2 results of irpagratinib combined with atezolizumab for advanced hepatocellular carcinoma at the 2025 ESMO GI Congress in Barcelona.
• The combination therapy demonstrated favorable safety profiles and promising anti-tumor activity in both treatment-naive and previously treated FGF19+ HCC patients, with previous data showing a 50% objective response rate.
• Irpagratinib, a highly-selective FGFR4 inhibitor targeting the FGF19 pathway overexpressed in approximately 30% of HCC patients, is positioned to potentially become the first approved FGFR4 inhibitor globally.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath